| Literature DB >> 33653742 |
Ji-Fei Hou1,2, Chuan Hu1,2, Yun Zhang3, Li-Qi Tian1, Yan-Zheng Liu4, Chi Zhang1,2, Jing Li1.
Abstract
BACKGROUND: Total joint arthroplasty (TJA), including total knee arthroplasty (TKA) and total hip arthroplasty (THA), is required for many patients. This study aimed to evaluate the medical costs, length of stay (LOS), blood transfusion and in-hospital complications in patients undergoing simultaneous and staged TJA.Entities:
Keywords: health economics; hip; knee; orthopaedic & trauma surgery
Mesh:
Year: 2021 PMID: 33653742 PMCID: PMC7929812 DOI: 10.1136/bmjopen-2020-041147
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
The introduction of all kinds of medical costs for patients
| Items | Description |
| Total medical expenses | The sum of health expenditures during hospitalisation |
| Bed fees | Relatively fixed expenses for the bed used by patients |
| Fees of general therapy | Including dressing change, injection, catheterisation, oxygen absorption and other costs |
| Nursing care fees | Relatively fixed cost of caring for patients every day |
| Check-up and laboratory test fees | Various medical equipment inspection costs |
| Surgical fees | The cost of the surgical operation alone, not including other expenses incurred during the hospitalisation |
| Drug fees | Refer in particular to drugs used by patients |
| Materials fees | A combination of various hygienic consumables cost |
Baseline characteristics of patients (prior to matching)
| Groups | TKA | THA | TJA | ||||||
| Variables | Simultaneous | Staged (n=391) | P value | Simultaneous | Staged (n=259) | P value | Simultaneous | Staged (n=650) | P value |
| Age, median (IQR) years* | 64 (60–69) | 68 (63–73) | <0.00 | 53 (47–60) | 58 (49–64) | 0.001 | 63 (58–68) | 64 (58–70) | 0.030 |
| Gender (female)† | 651 (82.51%) | 314 (80.31%) | 0.356 | 42 (30.00%) | 85 (32.82%) | 0.564 | 693 (74.60%) | 399 (61.38%) | <0.00 |
| BMI, median (IQR) kg/m2* | 27.34 (24.92–30.08) | 27.64 (25.39–30.04) | 0.149 | 24.55 (21.88–26.98) | 24.57 (22.58–27.55) | 0.279 | 26.99 (24.23–29.66) | 26.73 (24.03–29.30) | 0.119 |
| Hypertension (yes)† | 375 (47.50%) | 206 (52.69%) | 0.095 | 20 (14.29%) | 39 (15.10%) | 0.836 | 395 (42.52%) | 245 (37.69%) | 0.055 |
| Diabetes (yes)† | 124 (15.70%) | 71 (18.16%) | 0.228 | 7 (5.00%) | 9 (3.47%) | 0.459 | 131 (14.105%) | 80 (12.31%) | 0.303 |
| Coronary heart disease (yes)† | 126 (15.97%) | 64 (16.37%) | 0.861 | 1 (0.71%) | 4 (1.54%) | 0.477 | 127 (13.67%) | 68 (10.46%) | 0.057 |
| Disease of respiratory system (yes)† | 35 (4.44%) | 23 (5.88%) | 0.280 | 3 (2.14%) | 8 (3.09%) | 0.582 | 38 (4.09%) | 31 (4.77%) | 0.516 |
| History of cerebral infarction (yes)† | 48 (6.08%) | 21 (5.37%) | 0.623 | 2 (1.43%) | 4 (1.54%) | 0.928 | 50 (5.38%) | 25 (3.85%) | 0.158 |
*Continuous data were presented as median (IQR) and compared by Mann-Whitney U test.
†Categorical variables were expressed by counts and percentages and compared by the Χ2 test or the Fisher’s exact test, as appropriate.
BMI, body mass index; THA, total hip arthroplasty; TJA, total joint arthroplasty; TKA, total knee arthroplasty.
Baseline characteristics of patients (after matching)
| Groups | TKA | THA | TJA | ||||||
| Variables | Simultaneous (n=309) | Staged (n=309) | P value | Simultaneous (n=100) | Staged (n=100) | P value | Simultaneous (n=529) | Staged (n=529) | P value |
| Age, median (IQR) years* | 65 (62–65) | 66 (62–70) | 0.197 | 54 (50–62) | 57 (48–62) | 0.157 | 64 (59–69) | 64 (58–70) | 0.85 |
| Gender (female)† | 255 (82.50%) | 256 (82.80%) | 0.915 | 30 (30.00%) | 29 (29.00%) | 0.877 | 361 (68.20%) | 356 (67.30%) | 0.742 |
| BMI, median (IQR) kg/m2* | 27.47 (24.82–30.39) | 27.48 (25.34–29.48) | 1 | 25.32 (22.49–26.99) | 24.60 (22.60–27.65) | 0.48 | 26.40 (23.88–29.14) | 27.04 (24.22–29.36) | 0.05 |
| Hypertension (yes)† | 158 (51.10%) | 154 (49.80%) | 0.748 | 15 (15.00%) | 16 (16.00%) | 0.845 | 211 (39.90%) | 217 (41.0%) | 0.707 |
| Diabetes (yes)† | 56 (18.10%) | 46 (14.90%) | 0.279 | 2 (2.00%) | 2 (2.00%) | 1 | 59 (11.20%) | 70 (13.20%) | 0.301 |
| Coronary heart disease (yes)† | 45 (14.60%) | 53 (17.20%) | 0.378 | 2 (2.00%) | 2 (2.00%) | 1 | 54 (10.20%) | 56 (10.59%) | 0.84 |
| Disease of respiratory system (yes)† | 35 (4.44%) | 18 (5.80%) | 0.62 | 3 (3.00%) | 1 (1.00%) | 0.312 | 29 (5.50%) | 26 (4.90%) | 0.678 |
| History of cerebral infarction (yes)† | 21 (6.80%) | 18 (5.80%) | 0.261 | 1 (1.00%) | 1 (1.00%) | 1 | 24 (4.50%) | 20 (3.80%) | 0.538 |
*Continuous data were presented as median (IQR) and compared by Mann-Whitney U test.
†Categorical variables were expressed by counts and percentages and compared by the Χ2 test or the Fisher’s exact test, as appropriate.
BMI, body mass index; THA, total hip arthroplasty; TJA, total joint arthroplasty; TKA, total knee arthroplasty.
Clinical characteristics of patients (after matching)
| Groups | TKA | THA | TJA | ||||||
| Variables | Simultaneous | Staged (n=309) | P value | Simultaneous | Staged (n=100) | P value | Simultaneous | Staged (n=529) | P value |
| Complication (yes)† | 7 (2.27%) | 9 (2.91%) | 0.612 | 4 (4.00%) | 2 (2.00%) | 0.407 | 15 (2.80%) | 12 (2.30%) | 0.559 |
| LOS, median (IQR) days* | 9 (8–11) | 17 (15–20) | <0.000 | 9 (8–11) | 15 (14–18) | <0.000 | 9 (8–11) | 17 (15–20) | <0.000 |
| Blood transfusion (yes)† | 126 (40.78%) | 25 (8.09%) | <0.000 | 31 (31.00%) | 13 (13.00%) | 0.002 | 213 (40.30%) | 58 (11.00%) | <0.000 |
*Continuous data were presented as median (IQR) and compared by Mann-Whitney U test.
†Categorical variables were expressed by counts and percentages and compared by the Χ2 test or the Fisher’s exact test, as appropriate.
LOS, length of stay; THA, total hip arthroplasty; TJA, total joint arthroplasty; TKA, total knee arthroplasty.
The medical costs for all payment items during hospitalisation of patients
| Groups | TKA | THA | TJA | ||||||
| Variables | Simultaneous | Staged (n=309) | P value | Simultaneous | Staged (n=100) | P value | Simultaneous | Staged (n=529) | P value |
| Total medical expenses | 15 385 (14 415–16 450) | 16 729 (14 583–18 041) | <0.000 | 14 503 (12 548–16 771) | 16 142 (14 557–19 246) | 0.016 | 15 389 (12 378–16 533) | 16 830 (14 912–18 303) | <0.000 |
| Bed fees | 90 (76–110) | 158 (135–190) | <0.000 | 90 (77–112) | 152 (128–168) | <0.000 | 89 (76–112) | 157 (133–186) | <0.000 |
| Fees of general therapy | 102 (49–132) | 146 (105–180) | <0.000 | 101 (51–134) | 109 (58–168) | 0.671 | 98 (49–132) | 134 (80–176) | <0.000 |
| Nursing care fees | 60 (36–74) | 90 (61–111) | <0.000 | 60 (37–73) | 92 (65–115) | <0.000 | 60 (35–73) | 89 (60–113) | <0.000 |
| Check-up and laboratory test fees | 486 (440–563) | 1086 (907–1265) | <0.000 | 475 (428–544) | 925 (817–1120) | <0.000 | 487 (437–549) | 1052 | <0.000 |
| Surgical fees | 1012 (435–1085) | 1334 (903–1824) | <0.000 | 1080 (500–1305) | 1477 (983–1854) | <0.000 | 1012 (436–1139) | 1334 (906–1816) | <0.000 |
| Drug fees | 1355 (950–1879) | 2132 (1579–2499) | <0.000 | 1152 (868–1730) | 2056 (1405–2650) | <0.000 | 1302 (931–1785) | 2197 (1405–2595) | <0.000 |
| Materials fees | 11 236 (9500–13 398) | 12 015 (9702–12 703) | 0.334 | 11 652 (9503–13 920) | 11 697 (10 307–14 022) | 0.888 | 11 368 (9429–13 424) | 12 066 (10 299–12 953) | 0.325 |
All values are in US dollars (US$).
All medical expenditures were presented as median (IQR) and compared by the Mann-Whitney U test.
THA, total hip arthroplasty; TJA, total joint arthroplasty; TKA, total knee arthroplasty.